바이오스트림테크놀러지스

비상장계속사업자

Biostream Technologies Co.,Ltd.

강박운

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

바이오스트림테크놀러지스

Business Reg. No. 1248177798 · CEO 강박운

I.Investment Overview

Target바이오스트림테크놀러지스 (1248177798)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명바이오스트림테크놀러지스
영문명Biostream Technologies Co.,Ltd.
대표자강박운
사업자등록번호1248177798
법인등록번호1301110064591
설립일2000.10.06

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW365.62021485.32022469.52023375.32024531.92025
영업이익100M KRW11.7202145.82022-252023-16.5202422.82025
순이익100M KRW14.4202139.92022-212023-19.420248.42025
Item20252024202320222021
자산총계453억원505.3억원418.8억원386.2억원284억원
부채총계248.6억원309.3억원203.4억원199.7억원184.6억원
자본총계204.4억원196억원215.4억원186.5억원99.4억원
매출액531.9억원375.3억원469.5억원485.3억원365.6억원
영업이익22.8억원-16.5억원-25억원45.8억원11.7억원
순이익8.4억원-19.4억원-21억원39.9억원14.4억원

VI.Financial Ratios

FY2025 basis

4.29%

영업이익률

1.58%

순이익률

1.85%

ROA

4.1%

ROE

121.65%

부채비율

45.12%

자기자본비율

VII.R&D Activity

Fields 보건의료 > 신약·의약품개발 · 농림수산식품 > 식품과학 · 생명과학 > 산업바이오

Keywords 효능평가, 인간화 항체, 건강기능식품, 고지혈증, 치료용 항체

YearProjectsPapersPatents
2025210
2024200
2023010
2022200
2021100
2020102
2018002
2016000
2015100
2014100

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

바이오스트림테크놀러지스 투심보고서 | Alpha Lenz